Notice to Intent to Sole Source - Bio-Plex Reagents

SOL #: NOI-CC-26-002244Special NoticeSole Source

Overview

Buyer

Health And Human Services
National Institutes Of Health
NATIONAL INSTITUTES OF HEALTH - CC
BETHESDA, MD, 20892, United States

Place of Performance

Bethesda, MD

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

PSC

In Vitro Diagnostic Substances, Reagents, Test Kits And Sets (6550)

Set Aside

No set aside specified

Timeline

1
Posted
Feb 4, 2026
2
Action Date
Feb 14, 2026, 5:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The National Institutes of Health, Clinical Center (NIH-CC) has issued a Notice of Intent to Sole Source for Bio-Plex Reagents from Bio-Rad Laboratories. This acquisition is for Bio-Plex Pro Human Cytokine Screening Panel, 48-Plex kits, Bio-Plex Calibration kit, and Validation kit, essential for clinical CAR-T potency testing. Capability statements from responsible sources are due by February 14, 2026, 12:00 PM EST.

Scope of Work

The NIH-CC, Center for Cellular Engineering (CCE), requires these Bio-Plex products for CAR-T cell potency testing throughout the development and manufacturing of CAR-T cells. Key features and benefits of the Bio-Plex Pro Human Cytokine Screening Panel, 48-Plex, calibration, and validation kits include:

  • Designed for quantification of a panel of 48 cytokines, chemokines, and growth factors.
  • Usable with various sample types, including serum, plasma, and culture supernatant.
  • Compiles profiles of a series of cytokine and chemokine markers, providing more data from each sample.
  • Highly suitable for researchers seeking predictive biomarkers using small sample volumes (12.5ul per well).
  • Assays can be run in a significantly shorter time (~2 hours) compared to conventional ELISA techniques.
  • Ready-to-use validation and calibration kits with unique individual vials of each reagent.

Contract & Timeline

  • Type: Special Notice (Notice of Intent to Sole Source)
  • Vendor: Bio-Rad Laboratories
  • Duration: Three months (May 1, 2026 - August 1, 2026)
  • Set-Aside: None (Sole Source)
  • Response Due: February 14, 2026, 12:00 PM EST
  • Published: February 4, 2026
  • Place of Performance: Bethesda, MD

Evaluation

This is not a Request for Proposal. The government intends to negotiate on an other than full and open competition basis with Bio-Rad Laboratories, citing 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 (only one responsible source). All responsible sources that could provide the required items may submit a capability statement for consideration. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

Additional Notes

Submissions should be sent via email to valerie.gregorio@nih.gov with the subject line "NOI-CC-26-002244".

People

Points of Contact

No contacts available

Files

Files

Download
Download

Versions

Version 1Viewing
Special Notice
Posted: Feb 4, 2026
Notice to Intent to Sole Source - Bio-Plex Reagents | GovScope